Oncology Exchange
Frequently Asked Questions Regarding the Management of Multiple Myeloma in the Community Setting
Breast Cancer - Emerging Agents in Her2-postitive Breast Cancer
Emerging Strategies for the Management of Recurrent Ovarian Cancer
Non-Hodgkin's Lymphoma - Emerging Agents in Relapse/Refactory Non-Hodgkin's Lymphoma
Gastrointestinal Stromal Tumors - Emerging Multidisciplinary Approaches for the Management of Gastrointestinal Stromal Tumors
Challenges in Treating Renal Cell Carcinoma in the Community
Current Treatment Strategies for Chronic Myelogenous Leukemia
Personalizing Treatment for NSCLC An Oncology Exchange Program
Evidence-based Management of Metastatic Colorectal Cancer
Evolving Treatment Strategies for Mantle Cell Lymphoma in Elderly Patients
Emerging Strategies in Newly Diagnosed and Relapsed/Refractory Hodgkin Lymphoma
Rockpointe.com The confluence of medical science and clinical need

Oncology Exchange:
Current Treatment Strategies for Chronic Myelogenous Leukemia

A series of Live Grand Rounds Programs and an on-demand CME-certified Webcourse (Click here)

Welcome to "Oncology Exchange: Current Treatment Strategies for Chronic Myelogenous Leukemia". This CME-certified initiative is intended for community-based hematologists/oncologists and other health care professionals involved in the care of patients with chronic myelogenous leukemia. A series of live CME -certified programs will be presented at selected hospitals throughout the US during 2013/2014, and an online CME-certified webcourse is available as of September 2013.

Program Description:

The treatment algorithm for chronic myelogenous leukemia (CML) has evolved significantly with newly approved drugs and emerging data from ongoing clinical studies of novel treatment regimens in CML. Community clinicians are constantly challenged to stay up to date with recent advances in treatment, monitoring, and management of adverse events in CML.

Oncology Exchange: Current Treatment Strategies for Chronic Myelogenous Leukemia will use clinical case scenarios to provide guidance on the optimal treatment algorithms for the management of CML, while also exploring common issues faced by community clinicians involved in the treatment of CML patients.

Accreditation Statements:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statements:

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For information about the accreditation of this program, please email contact@rockpointe-pcme.com.

Calendars for Live Activities

Back to Top

Visiting Professor Series

Related Online Offerings

Back to Top

A calendar of live events, as well as additional CME-certified online activities, for this and other Oncology Exchange programming, can be found at: www.medscape.org/viewcollection/32391.

This program also has an associated webcourse. Click here to visit the enduring activities.

Live Program Materials for Speakers and Administrators

Back to Top

I. Administrator Material

II. Speaker Material

Audio Orientation

Thank you for joining us as an expert speaker for the 2013 Visiting Professor Series, "Oncology Exchange: Current Treatment Strategies for Chronic Myelogenous Leukemia."

This orientation will familiarize you with the complete slide set, provide insight from the program steering committee, and address potential questions. During the audio lecture, the following key topics will be discussed:

Identify changes in therapeutic indications and clinical practice guidelines for CML; Understand practical aspects of monitoring responses in patients with CML; Identify the role of BCR-ABL mutations in making treatment decisions in CML; Review emerging data from ongoing studies of novel treatment regimens and evaluate ongoing clinical trials of investigational agents.

This program has been recorded by the steering committee for use as an enduring webcourse. Speakers may use this webcourse as a speaker orientation.
Download Transcript (PDF)

Audio download of Speaker Orientation (ComingSoon)

Audio Download

CME-certified Program Slides

This version of the program slides has been CME-certified and these slides are to be used for this activity. Download (PowerPoint)

Steering Committee and Speaker Biographies

Back to Top

D.B. Lane Cancer Research
Distinguished Professor for Leukemia Research
Deputy Chairman, Section Chief of AML and CML
Department of Leukemia
University of Texas MD Anderson
Cancer Center
Houston, TX

JORGE CORTES, MD, is Deputy Chair and Professor of Medicine in the Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston, TX, where he directs the CML and AML Programs. Dr. Cortes received his medical degree in 1986 from the Universidad Nacional Autonoma de Mexico, in Mexico City, and has been at MD Anderson Cancer Center since 1991.

Dr. Cortes' clinical interests focus on new drug development and the management of patients with myelodysplastic syndromes, acute and chronic leukemias, and myeloproliferative disorders. He has authored more than 650 peer-reviewed medical publications, and has received numerous awards including the Faculty Scholar Award from MD Anderson Cancer Center in 2003, the Annual Celgene Young Investigator Achievement Award for Clinical Research in Hematology in 2005, the Dr. John J. Kenny Award from the Leukemia & Lymphoma Society in 2006, the Service to Mankind Award from the Leukemia & Lymphoma Society in 2007, and the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research from MD Anderson Cancer Center in 2007.

Dr. Cortes is chief editor of Current Hematological Malignancies Reports and Co-Chief-Editor of Clinical Lymphoma, Myeloma and Leukemia. He also serves on the Editorial Board of the Journal of Clinical Oncology, Clinical Cancer Research, Leukemia and Lymphoma, and the American Journal of Hematology. Dr. Cortes is a member of the Board of Directors of the Leukemia and Lymphoma Society and President of the Latin American LeukemiaNet.

Alexander J. Trotman Professor
Associate Director for Translational
Research Comprehensive Cancer Center
University of Michigan Hospital and Health System
Ann Arbor, MI

MOSHE TALPAZ, MD is the first Alexander J. Trotman Professor of Leukemia Research, and the Director for Translational Research at the Comprehensive Cancer Center at the University of Michigan Health System in Ann Arbor. Dr. Talpaz completed his medical training at the Hebrew University and Hadassah Medical School in Jerusalem, Israel, and his residency in internal medicine at the Kaplan Hospital in Rehovot, Israel. After a postdoctoral fellowship at the University of Texas MD Anderson cancer center in Houston, Dr. Talpaz joined the faculty of the cancer center in 1981 as an Assistant Professor of Medicine and then tenured Professor of Medicine. He was the Chairman of the Bioimmunotherapy Department and holder of the David Bruton Chair for Cancer Research before joining the University of Michigan faculty in 2006.

Dr. Talpaz's academic career has intertwined with therapeutic developments in chronic myeloid leukemia (CML). During a period of 30 years, Dr. Talpaz pioneered the development of interferon therapy for CML and was one of 3 investigators who conducted the first clinical studies with a renowned targeted therapy for CML. He later pioneered the development of a new targeted therapy for CML, and this work was published in the New England Journal of Medicine.

Dr. Talpaz has developed a large program dealing with CML at the University of Michigan and, as a result, was asked to lead the development of a novel and exciting new drug (a third-generation BCR-ABL inhibitor) for resistant CML, which was recently approved by the FDA.

Throughout the years, Dr. Talpaz has also been involved with translational research on the mechanism of drug resistance in CML, disease progression, and molecular aspects of CML. He has published more than 450 scientific articles and numerous reviews and book chapters on CML. More than anything, he sees himself as fortunate for being able to be part of this remarkable evolution in therapy, which may have a major impact on the treatment of cancer as a whole.

Back to Top
©2013 PCME